247 related articles for article (PubMed ID: 7956717)
1. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Wolf HR
Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
[TBL] [Abstract][Full Text] [Related]
2. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
Krüger B
Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
[TBL] [Abstract][Full Text] [Related]
4. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
[TBL] [Abstract][Full Text] [Related]
5. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
[TBL] [Abstract][Full Text] [Related]
6. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
Füsgen I; Summa JD
Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
[TBL] [Abstract][Full Text] [Related]
7. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher P; Scheuermann E; Lang W
Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers.
Koskinen P; Kovanen PT; Tuomilehto J; Manninen V
Arch Intern Med; 1992 Jan; 152(1):90-6. PubMed ID: 1728934
[TBL] [Abstract][Full Text] [Related]
10. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Dobiásová M; Frohlich J
Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
[TBL] [Abstract][Full Text] [Related]
11. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
Corominas Vilardell A; de Oya Otero M; Escobar Jiménez F; Anguera Vila A; Ariño Armengol B
An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868
[TBL] [Abstract][Full Text] [Related]
12. [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
Bertolami MC; Martinez TL; Faludi AA; Pinto LE; Melo RS; Bismarck ZF; Batlouni M
Arq Bras Cardiol; 1991 May; 56(5):407-12. PubMed ID: 1823741
[TBL] [Abstract][Full Text] [Related]
13. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
15. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
Bröijersén A; Hamsten A; Silveira A; Fatah K; Goodall AH; Eriksson M; Angelin B; Hjemdahl P
Thromb Haemost; 1996 Aug; 76(2):171-6. PubMed ID: 8865525
[TBL] [Abstract][Full Text] [Related]
16. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
Vessby B; Lithell H; Boberg J; Hellsing K; Werner I
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):32-7. PubMed ID: 798194
[TBL] [Abstract][Full Text] [Related]
17. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
18. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome.
Büyükçelik M; Anarat A; Bayazit AK; Noyan A; Ozel A; Anarat R; Aydingülü H; Dikmen N
Turk J Pediatr; 2002; 44(1):40-4. PubMed ID: 11858378
[TBL] [Abstract][Full Text] [Related]
19. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
[TBL] [Abstract][Full Text] [Related]
20. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Kovács I; Tarján J; Császár A
Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
